Stocks › NHI
National Health Investors, Inc. (NHI) stock analysis
SKIP 3% confidence · analysed Sep 9, 2026
This analysis is from Sep 9, 2026 and may be out of date.
On Sep 9, 2026, our model rated National Health Investors, Inc. (NHI) SKIP with 3% confidence at a price of $71.42. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 39. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.0x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $89.29 and the swing low is $67.13; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 4.76, which looks expensive relative to its growth.
The company reports a profit margin of 38.3% and revenue growth of -2.6%.
In its latest quarter it earned $1.15 per share, which missed the $4.57 analysts expected, with revenue +33.8% year over year.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $81.88.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Research notes
National Health Investors (NYSE: NHI) looks supported by a moderate-buy analyst backdrop, a roughly 5.2% dividend yield, and the company’s reported progress on deleveraging after selling its NHC portfolio for $560 million**, which management said reduced leverage and freed up capital for reinvestment.
The bull case is that NHI should benefit from solid senior housing and skilled nursing fundamentals, plus a balance sheet that appears more flexible after the portfolio sale; recent brokerage coverage still shows more buys than holds or sells, with an average target around $83.57 versus a recent price near $70.90–$71.73.
The bear case is that several firms have lowered price targets, Truist cut its target to $80 from $81 on lower FFO estimates, and the stock has been described as fairly valued at current levels, which suggests less room for multiple expansion if growth disappoints.
The main recent catalyst is the Q2 2026 earnings / portfolio-sale news flow, highlighted by the $560 million NHC portfolio sale and the associated sentiment around improved leverage and reinvestment capacity, alongside fresh analyst target revisions and rating updates.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.03 (SKIP). Technicals: RSI 39.09, MACD bearish, price below SMA50. Fundamentals: PEG 4.76, margin 38.3%, revenue growth -2.6%. Financial results: YoY revenue +33.8%, last EPS surprise -74.8%, next earnings 2026-11-05. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block, price retesting a bearish order block, sitting inside an unfilled bullish fair value gap. FinGPT news read: positive. Internet research: **National Health Investors (NYSE: NHI)** looks supported by a **moderate-buy analyst backdrop**, a roughly **5.2% dividend yield**, and the company’s reported progress on **deleveraging** after selling its NHC portfolio for **$560 million**, which management said reduced leverage and freed up capital for reinvestment. The **bull case** is that NHI should benefit from solid **senior housing and skilled nursing fundamentals**, plus a balance sheet that appears more flexible after the portfolio sale; recent brokerage coverage still shows more buys than holds or sells, with an average target around **$83.57** versus a recent price near **$70.90–$71.73**. The **bear case** is that several firms have **lowered price targets**, Truist cut its target to **$80 from $81** on lower FFO estimates, and the stock has been described as fairly valued at current levels, which suggests less room for multiple expansion if growth disappoints. The main **recent catalyst** is the **Q2 2026 earnings / portfolio-sale news flow**, highlighted by the **$560 million NHC portfolio sale** and the associated sentiment around improved leverage and reinvestment capacity, alongside fresh analyst target revisions and rating updates. Reference price $71.44; no trade levels (SKIP).
Past ratings for NHI
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 9, 2026 | SKIP | 3% | $71.42 | — |
"Move since" compares each call's price with the latest analysed price.
Other Real Estate stocks we cover
NLY · NTST · NXRT · ORC · OUT · PMT · REFI · RITM · RYN · SPG · STWD · VICI
Frequently asked questions
Is NHI a buy right now?
As of Sep 9, 2026, our automated model rates National Health Investors, Inc. (NHI) SKIP with 3% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does National Health Investors, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.